| Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline AA Wright, K Bohlke, DK Armstrong, MA Bookman, WA Cliby, ... Journal of Clinical Oncology 34 (28), 3460-3473, 2016 | 713 | 2016 |
| A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies C Aghajanian, S Soignet, DS Dizon, CS Pien, J Adams, PJ Elliott, ... Clinical cancer research 8 (8), 2505-2511, 2002 | 617 | 2002 |
| Digitizing clinical trials OT Inan, P Tenaerts, SA Prindiville, HR Reynolds, DS Dizon, ... NPJ digital medicine 3 (1), 1-7, 2020 | 292 | 2020 |
| Communicating uncertainty can lead to less decision satisfaction: a necessary cost of involving patients in shared decision making? MC Politi, MA Clark, H Ombao, D Dizon, G Elwyn Health Expectations 14 (1), 84-91, 2011 | 251 | 2011 |
| Clinical cancer advances 2016: annual report on progress against cancer from the American Society of Clinical Oncology DS Dizon, L Krilov, E Cohen, T Gangadhar, PA Ganz, TA Hensing, ... Journal of Clinical Oncology 34 (9), 987-1011, 2016 | 242 | 2016 |
| Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer S Makhija, LC Amler, D Glenn, FR Ueland, MA Gold, DS Dizon, V Paton, ... Journal of Clinical Oncology 28 (7), 1215-1223, 2010 | 219 | 2010 |
| Practical guidance: the use of social media in oncology practice DS Dizon, D Graham, MA Thompson, LJ Johnson, C Johnston, MJ Fisch, ... Journal of oncology practice 8 (5), e114-e124, 2012 | 218 | 2012 |
| Progress and remaining challenges for cancer control in Latin America and the Caribbean K Strasser-Weippl, Y Chavarri-Guerra, C Villarreal-Garza, BL Bychkovsky, ... The lancet oncology 16 (14), 1405-1438, 2015 | 212 | 2015 |
| Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial JF Liu, C Herold, KP Gray, RT Penson, N Horowitz, PA Konstantinopoulos, ... JAMA oncology 5 (12), 1731-1738, 2019 | 207 | 2019 |
| Vulvar cancer, version 1.2017, NCCN clinical practice guidelines in oncology WJ Koh, BE Greer, NR Abu-Rustum, SM Campos, KR Cho, HS Chon, ... Journal of the National Comprehensive Cancer Network 15 (1), 92-120, 2017 | 195 | 2017 |
| Sexual health as a survivorship issue for female cancer survivors DS Dizon, D Suzin, S McIlvenna The oncologist 19 (2), 202-210, 2014 | 169 | 2014 |
| Importance of clarifying patients’ desired role in shared decision making to match their level of engagement with their preferences MC Politi, DS Dizon, DL Frosch, MD Kuzemchak, AM Stiggelbout Bmj 347, 2013 | 163 | 2013 |
| Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology GA Masters, L Krilov, HH Bailey, MS Brose, H Burstein, LR Diller, ... Journal of Clinical Oncology 33 (7), 786-809, 2015 | 159 | 2015 |
| Quality of life after breast cancer: survivorship and sexuality DS Dizon The breast journal 15 (5), 500-504, 2009 | 159 | 2009 |
| Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma P Sabbatini, C Aghajanian, D Dizon, S Anderson, J Dupont, JV Brown, ... Journal of clinical oncology 22 (22), 4523-4531, 2004 | 159 | 2004 |
| Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer C Aghajanian, DS Dizon, P Sabbatini, JJ Raizer, J Dupont, DR Spriggs Journal of clinical oncology 23 (25), 5943-5949, 2005 | 156 | 2005 |
| Clinical cancer advances 2017: annual report on progress against cancer from the American Society of Clinical Oncology HJ Burstein, L Krilov, JB Aragon-Ching, NN Baxter, EG Chiorean, ... Journal of Clinical Oncology 35 (12), 1341-1367, 2017 | 155 | 2017 |
| Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown … WM Sikov, DS Dizon, R Strenger, RD Legare, KP Theall, TA Graves, ... Journal of Clinical Oncology 27 (28), 4693-4700, 2009 | 149 | 2009 |
| Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation KS Satyan, N Swamy, DS Dizon, R Singh, CO Granai, L Brard Gynecologic oncology 103 (1), 261-270, 2006 | 148 | 2006 |
| Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model … DS Dizon, ML Hensley, EA Poynor, P Sabbatini, C Aghajanian, ... Journal of clinical oncology 20 (5), 1238-1247, 2002 | 144 | 2002 |
Carol Aghajanian, MDChief, Gynecologic Medical Oncology Service, Memorial Sloan Kettering Cancer CenterVerified email at mskcc.org
